Medical/Pharmaceuticals
Seegene's COVID-19 test with saliva sample collection feature now available in Europe
SEOUL, South Korea, Jan. 6, 2021 /PRNewswire/ -- South Korea's biotechnology company specializing in molecular diagnostics, Seegene Inc. (KQ096530) said Tuesday that it has CE-IVD marked the saliva-based testing application for Allplex™ SARS-CoV-2 Assay and Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay...
2021-01-06 15:45
1983
JOYSBIO's COVID-19 antigen test kit is capable of detecting the new SARS-COV-2 strain found in the United Kingdom and the United States
BINHAI, Tianjin, Jan. 6, 2021 /PRNewswire/ -- As the world watches a concerning new strain of SARS-COV-2 first identified in theUnited Kingdom, one global biotech company has announced that their antigen test kit can detect the variant. JOYSBIO Biotechnology Co.'s SARS-CoV-2 Antigen Rapid Test K...
2021-01-06 15:11
2746
Connect Biopharma Establishes Scientific Advisory Board Comprised of Clinical Development and Program Indication Experts
Company's product development strategies to be enhanced by deep experience in dermatology, allergy and inflammatory diseases and successful drug approvals SAN DIEGO and TAICANG, SUZHOU, China, Jan. 5, 2021 /PRNewswire/ -- Connect Biopharma, a global clinical-stage biopharmaceutical company focuse...
2021-01-05 21:00
2424
Gift of Life Donor Program Leads U.S. in Organ Donation for 13th Consecutive Year
Region Demonstrates Extraordinary Generosity and Clinical Leadership Despite Pandemic Challenges: Most Organ Donors Every Year Since 2008 PHILADELPHIA, Jan. 5, 2021 /PRNewswire/ -- For the 13th consecutive year, Gift of Life Donor Program leads the nation in the most organ donors among all 58 U....
2021-01-05 20:43
3555
Global Cord Blood Announces NHC Policy Update
HONG KONG, Jan. 5, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today reported thatChina's National Health Commission ("NHC") ...
2021-01-05 20:30
11921
Chiauranib, an Anti-tumor Drug Developed by Chipscreen, is Given CDE "Breakthrough Therapy Designation"
SHENZHEN, China, Jan. 5, 2021 /RPNewswire/ -- Last December 25, the anti-tumor drug candidate Chiauranib, developed by Shenzhen Chipscreen Biosciences Co., Ltd., was granted with the "Breakthrough Therapy Designation Drug" by the Center for Drug Evaluation (CDE) and currently enter a phase III cl...
2021-01-05 17:49
2995
Terumo Enters 100th Anniversary Year
TOKYO, Jan. 5, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543) is celebrating its 100th anniversary this year - marking 100 years of 'Contributing to Society through Healthcare' onSeptember 17, 2021. The company has established 'Stride Ahead' as a slogan, to celebrate and connect all Terumo ...
2021-01-05 15:00
11667
Y-Biologics signed License Agreement with 3D Medicines for T cell bispecific engager in Greater China territory
DAEJEON, South Korea and SHANGHAI, Jan. 5, 2021 /PRNewswire/ -- The South Korean biotech company Y-Biologics and theChina-based biopharmaceutical company 3D Medicines have entered into a License Agreement granting exclusive rights to develop, manufacture, and commercialize YBL-013, a T cell bi-sp...
2021-01-05 09:00
2660
Ascentage Pharma Announces its 9th Orphan Drug Designation from the US FDA in 2020, Setting a Record for Chinese Biopharmaceutical Companies
SUZHOU, China and ROCKVILLE, Md., Jan. 5, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Adm...
2021-01-05 08:32
3085
Antengene Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer
SHANGHAI and HONG KONG, Jan. 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncolo...
2021-01-05 08:00
3872
AGC Biologics Confirms Cell and Gene Therapy Commercial Expertise as Manufacturer of Orchard Therapeutics' Newly Approved Libmeldy(TM)
SEATTLE, Jan. 4, 2021 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), is the first manufacturer of Orchard Therapeutics' Libmeldy™, which was recently approved by the European Commission (EC) as a one-time therapy for ...
2021-01-04 22:30
4056
INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China
PLYMOUTH MEETING, Pa. and SUZHOU, China, Jan. 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("A...
2021-01-04 21:00
5173
PharmAbcine to participate in BIO @ JPM and Biotech Showcase Digital during "J.P. Morgan Week 2021"
DAEJEON, South Korea, Jan. 4, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will participate in BIO @ JPM and Biotech Showcase during the J.P. Morgan Wee...
2021-01-04 21:00
1961
Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL
SHANGHAI and HONG KONG, Jan. 4, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncolo...
2021-01-04 08:00
4572
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib
Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms Consistent trends demonstrate greater improvement in reducing oxygen requirement by end of ...
2020-12-31 22:38
8765
ImmVira Announces Series C Financing with Leading Specialist Investors
SHENZHEN, China, Dec. 31, 2020 /PRNewswire/ -- ImmVira Group Company ("the Company"), a biotechnology platform dedicated to the development of oncolytic virus("OV") and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of Series C fina...
2020-12-31 19:29
4021
Eurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidate
STOCKHOLM, Dec. 31, 2020 /PRNewswire/ -- Eurocine Vaccines AB ("Eurocine Vaccines" or the "Company") has today selected Biovian Oy,Turku, Finland, ("Biovian") as the contract developer for the Company's vaccine candidate against chlamydia. Biovian, which is an internationally recognized contract ...
2020-12-31 10:42
2507
WinHealth and Immedica enter agreement giving Winhealth rights to Ravicti® in China and several other Asia-Pacific countries
STOCKHOLM and HANGZHOU, China, Dec. 31, 2020 /PRNewswire/ -- Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory coveri...
2020-12-31 09:00
5294
Modern Chinese Medicine Group Co., Ltd. to raise a maximum of approximately HK$221 million by way of Public Offer and Placing
Highlights * The Group principally engages in the production of proprietary Chinese medicine (the "PCM") in particular, and the Group offers both OTC and prescribed medicines intended for use by the Middle-aged and the Elderly in the PRC. * During the Track Record Period and up to 21 Decembe...
2020-12-30 23:38
15506
Yuyu Pharma was recognized as "Family-Friendly Company" by the Ministry of Gender Equality and Family
SEOUL, South Korea, Dec. 30, 2020 /PRNewswire/ -- Yuyu Pharma(CEO Robert Wonsang Yu, KRX: 000220) received recognition from the Ministry of Gender Equality and Family for implementing family-friendly policies for their employees. This is the second-time Yuyu has received this certification from ...
2020-12-30 22:00
3543
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
2025 Guangzhou Design Week Opens: PHOMI Holdings Leads Tech Innovation in Architectural Aesthetics
[Picked up by 287 media titles]
2025-12-06 10:37
Most Read
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
2025-12-06 09:00
4847
PAVS Achieves 18,037% YoY Revenue Increase in 2025 Interim Results
2025-12-05 21:45
4093
MALAYSIA REMAINS COMMITTED TO ACCELERATE TRANSFORMATIVE SOLUTIONS FOR A SUSTAINABLE AND INCLUSIVE FUTURE
2025-12-06 00:41
3950
Taipei City's Global Pass: A New Partner Channel for Global Startup Spaces
2025-12-06 01:06
3868
